Why Fulcrum Therapeutics Stock Is Back in Focus Fulcrum Therapeutics (FULC) is back on investors' radar after the company scrapped development of its lead sickle cell disease drug, pociredir, and ...

― Decision follows FDA feedback regarding the implications of the secondary malignancies observed with Tazverik ® (tazemetostat) and the product’s subsequent global withdrawal on the benefit-risk ...

The rocker arm employs the use of a fulcrum or pivot to increase the cam lift by a given ratio. That increase in lift is the result of moving the pushrod pivot point closer to the fulcrum. That ...

Fulcrum Therapeutics said today it is scrapping its lead pipeline program to develop pociredir as a treatment for sickle cell disease (SCD) and launching a “comprehensive” review of strategic ...